PEN Earnings Prediction
The chart below shows how PEN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PEN sees a +2.07% change in stock price 10 days leading up to the earnings, and a +6.30% change 10 days following the report. On the earnings day itself, the stock moves by -0.80%. This data can give you a slight idea of what to expect for the next quarter's release.
PEN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
301.04M
11.11%
0.55%
Gross Margin
66.54%
1.45%
1.54%
Operating Margin
13.40%
17.75%
36.73%
Net Margin
9.81%
188.53%
-148.78%
EPS
0.75
226.09%
-148.39%
No Data Available
PEN Earnings Analysis
Penumbra, Inc. Corporation (PEN.N) Earnings Conference Call
Positive
Third Quarter Revenue Increase: Total revenue for the third quarter was $301 million, representing an increase of 11.1% year-over-year.
Thrombectomy Business Growth: U.S. thrombectomy business grew 21.2% year-over-year to $162.1 million, driven by continued adoption and market penetration.
FDA Clearance for CAVT Products: The company received FDA clearance for two new CAVT products, enhancing and building out an increasingly comprehensive CAVT portfolio.
Gross Margin Expansion: Gross margins expanded to 66.5%, up 90 basis points over the prior year period, reflecting strong performance by the U.S. thrombectomy franchise.
EBITDA Growth Trajectory: Adjusted EBITDA of $56.7 million for the third quarter of 2024 compared to $51.5 million in the same period last year, indicating a solid growth trajectory.
Negative
Revenue Decline Q3 2024: Total revenues for the third quarter ended September 30, 2024, were $301 million, a decrease of 1.9% compared to the same period last year.
International Revenue Decline: Our international regions decreased by 1.9% reported and 2.5% in constant currency, primarily due to a reduction in China revenue of $13.6 million.
Operating Expenses Comparison: Total operating expenses for the quarter were $160 million or 53.1% of revenue, compared to $144.5 million or 53.3% of revenue for the same quarter last year.
R&D Expense Increase: Research and development expenses for Q3 2024 were $22.6 million compared to $21 million for Q3 2023, indicating increased spending without corresponding revenue growth.
Cost Savings from Business Wind Down: We wound down our Immersive Health care business in the latter half of the quarter, resulting in GAAP operating expense savings of approximately $6 million.
PEN FAQs
How does PEN typically perform around its earnings report dates?
Is Penumbra, Inc. (PEN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PEN Earning Call Sentiment
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PEN.N
-0.36%Positive
The earnings call presents a mixed picture: strong U.S. thrombectomy growth and improved margins are positive, but reduced revenue guidance and regulatory challenges dampen sentiment. The stock buyback is a positive factor, but economic and operational risks, especially in China, pose concerns. The Q&A section reveals some uncertainties, particularly regarding international recovery and competition. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement.
